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Abstract Gliomas are brain tumours classified into four
grades with increasing malignancy from I to IV. The develop-
ment and the progression of malignant glioma largely depend
on the tumour vascularization. Due to their tissue heterogene-
ity, glioma cases can be difficult to classify into a specific
grade using the gold standard of histological observation,
hence the need to base classification on a quantitative and
reliable analytical method for accurately grading the disease.
Previous works focused specifically on vascularization study
by Fourier transform infrared (FTIR) spectroscopy, proving
this method to be a way forward to detect biochemical chang-
es in the tumour tissue not detectable by visual techniques. In
this project, we employed FTIR imaging using a focal plane
array (FPA) detector and globar source to analyse large areas
of glioma tumour tissue sections via molecular fingerprinting
in view of helping to define markers of the tumour grade.
Unsupervised multivariate analysis (hierarchical cluster anal-
ysis and principal component analysis) of blood vessel spec-
tral data, retrieved from the FPA images, revealed the fine
structure of the borderline between two areas identified by a
pathologist as grades III and IV. Spectroscopic indicators are
found capable of discriminating different areas in the tumour
tissue and are proposed as biomolecular markers for potential
future use of grading gliomas.
Keywords Glioma . Grading . Blood vessels . FTIR
spectroscopy . FPA imaging
Introduction
The most common central nervous system tumours in adults
are malignant gliomas. Considered the deadliest of human
cancers, they are characterized by a highly proliferative index,
aggressiveness and invasiveness, leading to short patient sur-
vival [1]. Gliomas are classified into four grades with increas-
ing malignancy from I to IV. At grade IV, glioblastomas are
among the most vascularized human tumours and may devel-
op de novo as primary glioblastoma or through progression
from the lower grade [2, 3]. The fact that microvascular pro-
liferation cannot be observed in low-grade gliomas has led to
the hypothesis that both the development and the progression
of malignant gliomas largely depend on angiogenesis, i.e.
representing a hallmark of the disease [4–6]. Current imaging
techniques based on visible contrast microscopy with chemi-
cal staining do not always allow for differentiating gliomas
from non-tumoural lesions or high-grade tumours from
lower-grade lesions, and this can severely impact the patient
care. Following the tumour resection, extemporaneous tissue
samples are analyzed by the anatomo-pathologist who will
need to make a diagnosis of the tumour criteria, in order to
give rapid information to the neurosurgeon during the opera-
tion that will help the patient for getting the best treatment.
Currently, the gold standard for prognosis remains to be the
expert opinion of pathologists, who visually examine samples
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of the histological tissue sections deposited on microscope
slides. Typical histological classification is based on key
criteria, such as cellular density, nuclear atypia, mitotic activ-
ity, necrosis and microvascular proliferation [7]. In spite of
using stained sections, sometimes it is difficult for the pathol-
ogist to strictly define the grade of a tumour; as a consequence,
around 30 % of samples are pathologically misclassified due
to their heterogeneity [8]. In this sense, we believe that a
complementary approach based on rapid and quantitative
analysis could provide clinicians with a helpful and powerful
tool to more accurately classify tumourous areas, for a quicker
diagnosis and easier grading of such an aggressive disease.
Fourier transform infrared (FTIR) microspectroscopy is a
well-known technique that allows for qualitative imaging
and quantitative analysis of the basic molecular components
of biological tissues. Moreover, this technique is quickly
establishing its efficacy as a tool for molecular histopathol-
ogy by detecting subtle chemical changes in human tissue
samples [9, 10]. It has been demonstrated that FTIR imag-
ing of tumour t issue combined with advanced
chemometrics for spectral data processing can highlight
significant spectral changes related to molecular inter- and
intra-tumoural heterogeneity not detectable by conventional
haematoxylin-eosin (H&E) or immunohistochemistry (IHC)
staining [11, 12]. In previous studies, we focused our work
on differentiating normal and tumour vasculature of human
gliomas by FTIR imaging [13]. In the same way, the anal-
ysis of subtle modifications of biomolecule content in the
blood vessels (BVs) could reveal tumour growth in differ-
ent stages [14]. We also studied BV microstructure using
conventional versus synchrotron source and combined
FTIR microanalysis with chemometrics to well define the
vessel structure [15]. In the present work, we used FTIR
imaging with a focal plane array (FPA) detector and con-
ventional source to study BVs in tumour tissue sections.
FPA technology allows rapid collection of thousands of
IR spectra on large tissue sample areas [16–18], and this
makes it a potential tool for clinical diagnosis and medical
assessment, especially in these kinds of tumour where the
rapid answer is essential for the neurosurgery outcome.
First, we assessed the FPA performances using different
binning modes by quickly screening mouse tumour tissue
sections as a test to determine which binning option is the
best. Then, we were particularly interested in acquiring
FPA images of human glioma sections from areas described
as grade III (GIII) and grade IV (GIV) in the same sample.
Tumour areas of the two different grades were assessed by
pathologists on parallel sections stained with H&E. The
aim is to establish features of the vascularity biomolecular
markers of the two grades. The most interesting finding in
this work is that FTIR-FPA imaging could provide a means
to revise the pathologist’s line of demarcation separating
GIII from GIV parts of a single section.
Materials and methods
Samples
Mouse xenografted tumours (resulting from subcutaneous
transplantation of rat C6 glioma cells) 3 weeks post-
implantation were cryo-microtomed (see [14] for full experi-
mental details). Sections of 10 and 20 μm in thickness were
transferred, respectively, to microscope slides for IHC staining
and to a zinc selenide (ZnSe) support for FTIR spectral imag-
ing. Human extemporaneous sample was obtained from a pa-
tient with glioblastoma. The patient consent was fully obtain-
ed. Twenty-micrometre-thick cryo-fixed tissue sections were
prepared by the Pathology Department of Bordeaux Univer-
sity Hospital and deposited on silicon (Si) wafers for IR mea-
surements. Serial sections of 10 μm in thickness were depos-
ited on microscopy slides for H&E and IHC staining. Tissue
sections were dried in air before FTIR microanalysis. For re-
vealing blood vessel location in parallel tissue sections and
defining the regions of interest, IHC using CD31 antibody
(for mouse tumour section) or CD34 antibody (for human
tumour section) was performed (as previously described in
[13] and [14]). All experiments performed in this work were
achieved in compliance with the relevant bioethics laws and
institutional guidelines in France.
FPA detector and binning
FPAs are multi-element mercury cadmium telluride (MCT)
detector arrays consisting of n×n pixels (where n=16, 32,
64, 128 and 256 as per current commercial technology). In
contrast to a single-element MCT detector, FPAs acquire si-
multaneously as many spatially resolved spectra as the detec-
tor elements. The result of one single measurement is a spec-
tra matrix analogous to the detector element matrix. The FPA
detector used in this study consists of 64×64 elements, for
which the pixel physical size is 40×40 μm2. The final mea-
sured area or field of view (FoV) depends on the actual FPA
size and magnification optics. In our case, the overall detector
area is 2560×2560 μm2, which by the ×15 Cassegrain objec-
tive and matching condenser, used for sample collection in
transmission mode, provides a FoV of circa 170×170 μm2
per one FPA tile. The pixel size on the sample is scaled by
the optics too; by the ×15 Cassegrain objective/condenser, the
effective pixel size over the sample (i.e. optical sampling) is
2.6 μm. The binning function is a pre or post process intended
for IR maps measured with an FPA detector. It calculates the
average spectrum of n×n spectra in a matrix and replaces
them with the calculated average spectrum. In this way, the
data quality can be significantly improved by reducing the
spectral noise but at the cost of spatial resolution; i.e. with
2×2 pixel binning, the effective pixel size at the sample be-
come 5.3 μm instead of 2.6 μm with the ×15 optics and the
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FPA used here. Another effect of the binning function is a
smaller file size since the number of spectra acquired is re-
duced. If each group of e.g. 2×2 or 4×4 spectra of the spectra
matrix is replaced with its average spectrum, the S/N ratio
improves by factor 2 or 4 and so on. Despite this positive
effect, one should take into consideration that the spatial res-
olution will be correspondently reduced by factor 2, 4, etc., at
the same time.
FTIR measurements
Images of samples were acquired using a Bruker system
(Bruker Optics, UK) available at the MIRIAM beamline
B22 at Diamond Light Source. The system consists of a Ver-
tex 80v spectrometer coupled to a Hyperion 3000 microscope
attached to the FPA detector described in the previous para-
graph. Spectra were collected in transmission mode with the
×15 optics at 4 cm−1 as spectral resolution and 32 scan co-
additions for the human tissue section (vs 128 background
scans) and 8 sample scans for the mouse tissue section (vs 8
background scans). Mouse tumour section was imaged by 80
FPA tiles (X=16 and Y=5). Different areas of the human sec-
tions were imaged, namely two small areas by 35 FPA tiles
(X=5, Y=7) and 42 FPA tiles (X=6, Y=7) and a bigger area by
228 FPA tiles (X=12, Y=19). IR maps were acquired with and
without pixel binning. Images from the mouse tumour section
served as a model for testing pixel binning to assess spectral
quality versus good spatial resolution. For this sample, we
tried different binning modes (2×2, 4×4 and 8×8). Small
images from the human section were acquired without pixel
binning. However, since the bigger image was a large area of
circa 6 mm2, it has been binned 2×2 at acquisition to keep a
high spatial resolution without exceeding the detector holding
time for cooling (about 5 h). Table 1 summarizes the binning
mode including the pixel size and the acquisition time for each
image.
FTIR spectral data analysis
Spectra of BVs were retrieved from integration false colour
maps based on the ratio of protein (1700–1500 cm−1) to the
CH stretching region (3000–2800 cm−1) as this helped to re-
veal BV structure (since this is not always evident in the un-
stained tissue section). The maps were correlated with the
images from IHC/H&E parallel stained sections. An average
spectrumwas taken for each BV, and all spectra were analyzed
by chemometric methods using Opus 7.2 software (Bruker,
Germany) and Unscrambler X 10.2 software (CAMO, Nor-
way). Specifically, hierarchical cluster analysis (HCA) and
principal component analysis (PCA) were the two chemomet-
ric methods that were applied to the data.
Results
Pixel binning
FTIR chemical images were achieved using an FPA multi-
element detector, and large maps were a combination of sev-
eral FPA tiles. A different pixel binning was performed on
both sample types as described in Table 1. Figure 1 shows
the mouse tumour section imaged in different binning modes,
the effective pixel size increases, but the number of spectra
and the acquisition time reduce when higher binning is per-
formed. Therefore, the amount of data handling is reduced as
well as the processing time for data analysis. From this figure,
it is clear that there is no major difference between 4×4 bin-
ning and 2×2 binning, although the pixel projection on the
sample is increased, which means that the spatial resolution is
reduced. This may depend on the fact that the main IR features
of interest were greater in size than the pixel projection size.
This can be better seen with the 8×8 binning, where the res-
olution has decreased and the small BV of about 17 μm in
diameter (indicated by black arrow) was giving less clear
structure with respect to the original 2×2 binning acquisition.
Still, a key advantage of binning is the smaller file size as the
number of spectra is reduced. This can be helpful when che-
mometric analysis (e.g. HCA or PCA) is performed on large
images where the high number of spectra limits the analysis
capabilities of available/commercial IR software suites. For
instance, using the Opus 7.2 software, the maximum number
of spectra that can be handled in an IR map by PCA is about
Table 1 Summary of the
acquired images by FPA Images FPA tiles (X×Y) Binning mode Pixel size at sample (μm) Acquisition time
Mouse image 0 80 (5×16) No binning 2.6 1 h and 10 min
Mouse image 1 2×2 5.3 30 min
Mouse image 2 4×4 10.6 20 min
Mouse image 3 8×8 21.3 19 min
Human image S1 42 (6×7) No binning 2.6 1 h and 10 min
Human image S2 35 (5×7) No binning 2.6 1 h
Human bigger image 228 (12×19) 2×2 5.3 3 h
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8000 (i.e. two FPA tiles acquired without binning) while the
limit for HCA analysis doubles the number of spectra (i.e. four
FPA tiles). When binning reduced the number of spectra to
roughly 5000 (Fig. 1e), PCA could be performed and the PC1
score plot (Fig. 1f) clearly reveals the BVs in the IR map.
It is also possible to perform binning post process; thus, it
would be advisable to acquire FPA images without or with 2×
2 binning to keep the highest spatial resolution in case of
working on small features. Also, there is no practical advan-
tage in acquisition time inmapping beyond 2×2 binning at the
start as per Table 1.
Human tumour sections
Small images
These were acquired without binning to have the maximum
resolution possible. Spectra from BVs were retrieved from the
integration maps and averaged to have one average spectrum
per BV. Image S1 was collected on an area identified by the
pathologist as a GIII area. For this area, there were ten spectra
representing BVs 1 to 10. Image S2 was collected on an area
identified by the pathologist as a GIV sub-section far from the
grade III sub-section. For this area, there were 16 spectra
representing BVs 11 to 26. We were interested in comparing
the characteristics of these different areas of gliomas refer-
enced as pure grade III or IVusing the IR spectral information
of the BVs issued from the FPA detector image (Fig. 2, show-
ing only image S2, image S1 is not shown for brevity). Spectra
from these small images were then analyzed using the Opus
7.2 software by HCA using the second derivative 13-point
Savitzky-Golay smoothing and vector normalization. The
two main regions suggested to classify the spectra were the
CH stretching (3000–2800 cm−1) and the fingerprint (1700–
1000 cm−1) regions as these cover the main absorption bands
in the full spectral range. The classification based on the fin-
gerprint region alone gave two separate clusters where the
BVs of each grade were grouped together without any mis-
classification (Fig. 3). The CH stretching region alone did not
classify the two clusters perfectly; thus, the combination of the
fingerprint and the CH stretching region did not improve the
classification obtained by the fingerprint region alone. There-
fore, we deduced that the main spectral region capable of
separating the two clusters was the fingerprint region.
As can be seen in Fig. 3, the major differences between the
second derivatives of the average spectra for each grade reside
in the following sub-regions: 1700–1675, 1595–1585, 1555–
1515, 1475–1450, 1290–1200 and 1050–1030 cm−1. Later,
we subdivided the fingerprint region into three wave number
intervals (1700–1500, 1500–1300 and 1300–1000 cm−1) to
show precisely what the differences are between the two
grades. These will be shown in the next paragraph to avoid
repetition and also will be based on the larger number of
spectra.
Bigger image
This IR map was acquired via 2×2 pixel binning in order not
to compromise the spatial resolution for the sake of revealing
smaller BV features. Spectra from BVs were retrieved from
Fig. 1 Mouse xenografted tumour section comparing different pixel
binning modes. (a) Visible image of the tumour section deposited on
ZnSe showing the FPA grid of about 2.3 mm2 area imaged with ×15
objective at 4 cm−1 and 8 scans co-added; BVs were circled for easy
recognition and better comparison with the false colour maps. (b) Parallel
section stained with CD31 to highlight all BVs. (c) Integration map
binned at 2×2, with 81,920 spectra, effective pixel size of 5.3 μm,
revealing clear BVs. (d) Integration map binned at 4×4, with 20,480
spectra, effective pixel size of 10.6 μm. (e) Integration map binned at
8×8, with 5120 spectra, effective pixel size of 21.3 μm. (f) PCA score
1 performed on binned 8×8 image as the number of spectra was reduced.
The black arrow points to a small BV for which the structure is less clear
with higher binning option. Scale bar (red bar in one FPA tile) in (a) is
171 μm
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Fig. 3 HCA dendrogram and average spectra graph for small human
glioma images. (a) Dendrogram comparing BV spectra between the
two small FPA images S1 GIII area (BVs 1–10) and S2 GIV area (BVs
11–26). Classification was based on the fingerprint region. (b) Average
spectra of BVs from each group for the fingerprint region (1700–
1000 cm−1). Spectra were second derivative, 13 points smoothed and
vector normalized. (c) Standard deviation plots of the BV second
derivative and vector-normalized spectra for each group for the finger-
print region. The same scale was respected in (b) and (c) graphs
Fig. 2 Human glioma section for
small image S2 (GIVarea). (a)
IHC section stained with CD34.
(b) Parallel section deposited on
Si wafer that shows the visible
image acquired with FPAwith
×15 objective at 4 cm−1 and 32
scans without binning. (c)
Protein-to-CH stretching ratio
integration map of the FPA
image. Scale bar (red in (b)) is
171 μm
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the protein-to-CH stretching ratio integration map and aver-
aged to have one average spectrum per BV. This image con-
tains two areas identified by the pathologists on the parallel
section stained with H&E (see Electronic Supplementary Ma-
terial (ESM) Fig. S1): one part as a GIII area (top part) and the
other part as a GIV area (bottom part). It is worth mentioning
that it is not always the case that pathologists can easily iden-
tify the grade or define the limits of the tumour. Both areas are
separated in the H&E-stained section (see ESM Fig. S1, mid-
dle) due to cutting (the thinner section can be easily split
during the cutting on the microtome or when deposited on
the slide). There was no separation between the two areas in
the thicker section deposited on Si wafer (see ESM Fig. S1,
right) and imaged by IR; therefore, visually in this section, it
makes it difficult to identify where the border between the two
areas is.
HCA analysis In the GIII area, there were 23 spectra identi-
fied for BVs numbered 1 to 23, and in the GIVarea, there were
35 spectra for BVs numbered 24 to 58. These spectra were
chosen after matching the two serial sections and drawing a
borderline to separate the two grades based on the limit of the
GIII area identified by the pathologist on the H&E section.
Spectra were then analyzed using the Opus 7.2 software using
the HCA method following the same procedure as for the
small images in the previous data (i.e. second derivative 13-
point Savitzky-Golay smoothing and vector normalization
over the fingerprint region 1700–1000 cm−1). HCA gave
two separate clusters where the BVs of each grade were
grouped together with some misclassification (Fig. 4a). Seven
BVs from the GIII area (named GIII since they originate
from the area identified as GIII based on the pathology
identification) were grouped with the GIV cluster. These
Fig. 4 HCA dendrogram and PCA graphs for human glioma big image
BV spectra. (a) HCA dendrogram comparing BV spectra between the
two areas identified by the pathologists as GIII and GIV. GIV BV
spectra are named with a plus sign to differentiate from GIII ones.
Classification based on fingerprint region shows seven BVs (13–15, 17,
18, 21 and 22, marked by blue stars) from the GIII group classified in the
GIV cluster. (b) PCA analysis confirms the misclassification of the same
BVs obtained in the HCA. (c) Loading vector of PC1 which separates
both groups based on the fingerprint region. Spectra were second
derivative, 13 points smoothed and vector normalized
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were spectra 13, 14, 15, 17, 18, 21 and 22 (marked by
blue stars in Fig. 4a).
PCA analysis To confirm the classification was not due to the
HCA method itself, PCA based on the fingerprint region was
independently performed using the Unscrambler X 10.2 soft-
ware and gave the same results as the HCA. PCA was per-
formed also on the second derivative spectra, 13-points
smoothed and vector normalized, using the non-linear itera-
tive partial least squares (NIPALS) algorithm and leverage
correction validation method. Figure 4b shows PCA based
on PC1 versus PC2 scores where PC1 separates the two clus-
ters, and the same seven BVs from GIII are grouped with the
GIV cluster (blue numbers in the red circle). It is noteworthy
that the influence Q-residual plot of PCA (referred as
Hotelling T2 suited to spot samples which may be regarded
as outliers for being too extreme in the model) grouped 97 %
of the data in the well-described part. There were no outliers
or not well-described samples.
Spectral markers The PC1 loading vector (Fig. 4c) could
identify the differences between the two groups, but in order
to highlight them better, second derivatives of the aver-
age spectra of each cluster were plotted together within
the fingerprint range for each of the sub-regions previ-
ously mentioned (1700–1500, 1500–1300 and 1300–
1000 cm−1) in Fig. 5.
In the 1700–1500 cm−1 sub-region corresponding to the
protein region where amides I and II are the two major bands,
few differences can be seen (Fig. 5b); the bands at 1681 cm−1
(more pronounced in GIII) and 1675 cm−1 (more pronounced
in GIV, almost inexistent in GIII) differ between the two
groups. These bands correspond to the β sheets and β turns,
respectively, of the protein secondary structure [14, 19]. This
can also be confirmed with the band at 1623 cm−1 (corre-
sponding toβ sheets) which is muchmore pronounced in GIII
compared to GIV. The intensity of the bands at 1654 and
1633 cm−1 corresponding respectively to the α-helix and tri-
ple helix of amide I (C=O stretching) is higher in the GIV
group with respect to the GIII group. The bands at 1549 and
1543 cm−1 as well as the bands at 1521 and 1515 cm−1 corre-
sponding to the C–N stretching and N–H bending vibrations
of the amide II band [20] change in the opposite direction
between the two groups. These changes are induced by the
Fig. 5 Average spectra graphs for human glioma big image of BVs of
each group of GIII and GIV based on the classification in Fig. 4. (a)
Absorbance spectra full range (spectra were offset for clarity). (b)
Second derivative spectra in the region 1700–1500 cm−1. (c) Second
derivative spectra in the region 1500–1300 cm−1. (d) Second derivative
spectra in the region 1300–1000 cm−1. Spectra were 13 points smoothed
and vector normalized. Peaks of interest are highlighted
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conformational changes in the protein secondary structure in
the BVs with the tumour progression.
In the 1500–1300 cm−1 range, where mostly lipids and
proteins absorb, the major difference that can be seen
(Fig. 5c) is around the two bands at 1471 and 1457 cm−1
corresponding respectively to the CH2 bending of the methy-
lene chain in lipids [21] and the asymmetric CH3 bending
mode of methyl groups in proteins [22]. The intensity of both
bands decreased in the GIV group compared to the GIII group.
In the 1300–1000 cm−1 range, the major difference can be
seen around the bands at 1285, 1239 and 1203 cm−1, which
correspond to amide III of collagen [23], and these have
higher intensity in the GIV group compared to the GIII group.
This difference could be due to the structural alteration of
collagen and its deformation with advanced tumour grade.
New boundary between the two grades Following the clas-
sification of the IR spectra retrieved from the bigger image of
the human tissue section with the two areas of GIII and GIV
being in contact, a new boundary between the two grade areas
could be drawn. This is shown in Fig. 6. First, the left panel
shows the visible image of the tissue section part which was
acquired by the FPAwith the red line defining the borderline
between the two areas identified by the pathology observation.
The second mid panel shows the protein-to-CH stretching-
integrated band ratio as a false colour IR intensity map with
the same red line drawn that separates between the BVs of the
GIII and GIV areas. In the far right panel, the same area is
shown with a new red line drawn separating the two areas
based on the HCA and the PCA classification of the BV IR
spectra. This was done by taking into consideration the seven
BVs originally labelled as GIII from the pathologist’s obser-
vation but then classified as GIV after IR analysis and
chemometrics with both methods. This mismatch could be
due to two reasons: (i) glioblastomas are known to be very
invasive and highly heterogeneous tumours; hence, a mix of
grades, especially for the advanced stages, is possible; (ii)
progression from GIII to GIVas described before is consistent
with mixed BV spectra at the limit between the two grades. In
both cases, the molecular information of these BVs that could
be revealed by FTIR imaging helped to identify the borderline
between the two areas. It was not straightforward to do this
when comparing with the H&E-stained section (used for pa-
thology) where the two areas were separated and not
completely in contact.
Discussion
The accurate classification of human gliomas has many impli-
cations for the care of patients in estimating prognosis and
guiding therapy [24]. Assigning a precise grade is sometimes
not possible. Diffuse glioma grading is based on the World
Health Organization (WHO) criteria for astrocytomas and
oligodendrogliomas [25]. Pathological definitions of the
grades, e.g. atypia, mitoses, microvascular proliferation and
necrosis, could help the pathologist to diagnose the tumour
as being at least WHO grade III. Clinical features are similar
for grade III glioma and diffuse gliomaWHO grade II. Some-
times with a prior history of a diffuse grade II astrocytoma,
there are increasing neurological deficits. Some patients have
a shorter course without previous history of a glioma. For
glioblastoma WHO grade IV, the clinical history is usually
short (less than 3 months in more than 50 %). Surgery, radio-
therapy and chemotherapy are the treatments available for the
purpose, and there are treatment specificities between glioma
Fig. 6 Human glioma big image integration map. Left visible image
acquired with the FPA where there are two areas [GIII (top) and GIV
(bottom) separated by the red line].Middle protein-to-CH stretching ratio
integration map of the FPA image showing the BVs with their assigned
numbers and a red line splitting between the two grades as identified by
the pathologists. Right the same integration map but with a new red line
separating the two areas based on IR spectra classification by HCA and
PCA analysis
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grades and types; if the tumour is reachable, surgery is recom-
mended as a first step to remove as much as possible from the
tumour knowing that complete resection is often not feasible.
For WHO grade III glioma, it depends if it is an anaplastic
grade III oligodendroglioma or an oligoastrocytoma (radio-
therapy is preferred for little tumours, whereas radio-
chemotherapy is preferred for larger ones) or astrocytoma (ra-
diotherapy is the standard) [26, 27]. For glioblastoma WHO
grade IV, the Stupp design is the reference which associates
radiotherapy and temozolomide along with a specific plan
[28].
Pathologist’s observation is currently accredited as the ac-
curate tool to identify alterations in the structure of diseased
tissues, and glioma tumour classification depends on the ex-
perience of the observer and is subject to optimal sample con-
trast. In spite of using stained sections, sometimes it is difficult
for the pathologist to strictly define the grade of a tumour and
this can affect the patient follow-up treatment. Thus, a com-
plementary objective technique is needed in this sense. Since
the progression of the glioma tumours largely depends on the
angiogenesis and the microvascular proliferation, the key idea
is to study the BVs of these tumours by vibrational spectros-
copy to see if this can help to identify different issues. The
hypothesis was partially tested in previous published work.
The continuation is in progress to study different grades and
increase the grading factor library of these tumours based on
their vascularization. Apart from previous work published by
these authors, no other work has been reported in this field.
However, there are parallel works done by few groups to study
the bulk brain tumour tissue. Gajjar et al. reported that in
studying different types/grades of brain tumours by IR and
Raman spectroscopy, they were able to segregate various
grades of glioma more readily compared to current staining
methods [21]. Other studies [29, 30] also showed the potential
application of IR spectroscopy in diagnosing and grading gli-
omas based on the tumour tissue.
In this work, FTIR-FPA imaging was implemented to spe-
cifically study the tumour vascularization in order to prove its
potential to detect biochemical changes in the tumour tissue
which can be helpful for grading the tumour. Current technol-
ogy of FPA detector permits to quickly acquire IR maps over
large areas of tissue sections already in its standard version
with 64×64 pixel matrix. This is useful for rapid screening of
large tissue components and/or localization of areas of bio-
chemical interest. Good spectral quality is then provided at
single pixel size in which its projected size varies from
2.6 μm (×15 objective) to multiple of 2 when binning is per-
formed. Here, two types of samples were studied: (i) the
mouse tumour data served only as a test to determine which
binning option is the optimal. This was done to assess FTIR
imaging via an FPA detector and globar source in terms of
performances when analyzing large tumour tissue sections
using different binning modes without compromising the IR
image information content. We realized that binning beyond
2×2 was not beneficial for our specific samples, given the size
of the features of interest (as a rule of thumb, these should not
be smaller than the pixel projection size). If working on large
features, binning of 8×8 could be performed to reduce the file
size and perform further data analysis rapidly. (ii) The second
sample was a human glioma tissue. The aim was to check the
reliability of IR imaging via FPA screening when
implementing it to analyse large areas of glioma tissue section
of two different grades, i.e. astrocytomaGIII and glioblastoma
GIV. The use of FPA detector for IR mapping combined with
chemometric analysis allowed us to highlight BV spectro-
scopic markers not detectable by conventional H&E or IHC
staining. These markers helped to identify the borderline be-
tween two close areas of different grades (III and IV) in glio-
ma tissue sections. The biomolecular markers from the BVs,
revealed in the IR fingerprint spectral region (1700–
1000 cm−1), could be used as discriminating factors for differ-
entiating the areas of different glioma grades.
Regarding the data of the human glioma tumour, it is quite
rare to find a sample as the one studied in this work which
shows different grades in different areas (two separated re-
gions and two adjacent regions). Despite of having only one
sample that can limit the impact of the study, we believe that
this is a valid proof of principle for using IR imaging in glioma
grading. In particular, the spectral analysis based on a relative
comparison of different glioma grades on the same specimen
from the same patient overcomes the intrinsic complication
given by the bio-variability that the use of samples from dif-
ferent patients with only one/two specific grades could intro-
duce, especially for this kind of tumours known to be very
heterogeneous as previously mentioned. Although the human
brain samples are some of the most difficult to get hold of,
more samples with concomitant different grades from more
patients will be studied as soon as available. For this same
patient, IR imaging via an FPA detector was able to separate
the graded areas as GIII and IV both when spatially well
separated and adjacent. The major outcome of the work is
the proof of concept as the potential advantage of IR micro-
analysis over the pathological identification to establish the
borderline between the two graded areas based on the molec-
ular spectra, information not available by visual microscopy
where only the morphological aspect is evaluated.
Conclusion
The results of this project are a promising step forward for
implementing FTIR-FPA imaging as a reliable complementa-
ry label-free technique to grade gliomas. The revealed spectral
biomolecular markers from the glioma vascularization could
be used as discriminating factors for differentiating the areas
of different glioma grades. This study represents the proof of
IR imaging discriminates between two different glioma grades 7303
principle that a complementary spectroscopy technique like
FTIR—not based only on visual observation and experienced
observer—is a helpful tool for this specific biomedical re-
search on tumours. Although the data are limited, this work
clearly shows the potential advantage of FTIR microanalysis
over the pathological identification in defining the fine bor-
derline between two differently graded tumoural tissue areas.
More samples with concomitant different grades and from
more patient cases will be studied in the future.
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